From a clinical point of view, BRAF-mutated CRC behave as a distinct subset compared to conventional adenomas, typically exhibiting lower response to conventional therapy, elevated invasiveness and the poorest clinical outcome, suggesting that initiation through this pathway might predict the aggressiveness of CRC [6, 13]. This evidence concerns the gene BRAF and colorectal carcinoma.